Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.67 -0.30 (-0.55%)

Streaming Delayed Price Updated: 9:31 AM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗

February 02, 2025

Via The Motley Fool

Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox ↗

January 31, 2025

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

Via Benzinga

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

January 23, 2025

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

Via MarketBeat

My Top 5 Stocks to Buy in Early 2025 ↗

January 23, 2025

Via The Motley Fool

1 big new Green Flag for CRISPR Therapeutics' Stock ↗

December 20, 2024

Via The Motley Fool

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗

January 22, 2025

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Via Benzinga

3 Unstoppable Stocks to Buy in 2025 ↗

January 18, 2025

Via The Motley Fool

Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia ↗

January 18, 2025

Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.

Via Benzinga

Topics Artificial Intelligence

2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗

January 16, 2025

Via The Motley Fool

Vertex's Pain Drug: Big Pharma's Next Major Success?

January 16, 2025

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Via MarketBeat

My 10 Top Stocks to Buy to Start the New Year Off Right ↗

January 16, 2025

Via The Motley Fool

Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗

January 14, 2025

Via The Motley Fool

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

3 Mid-Cap Stocks That Could Take Off in 2025 ↗

January 09, 2025

Via The Motley Fool

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? ↗

December 22, 2024

Via The Motley Fool

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗

December 17, 2024

Via The Motley Fool

3 Things You Need to Know if You Buy CRISPR Therapeutics Today ↗

December 14, 2024

Via The Motley Fool

2 Biotech Stocks to Buy Hand Over Fist in December ↗

December 07, 2024

Via The Motley Fool

3 of the Best Growth Stocks You Can Buy for Less than $100 ↗

December 05, 2024

Via The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65% ↗

November 30, 2024

Via The Motley Fool

Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments ↗

November 29, 2024

Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation...

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? ↗

November 24, 2024

Via The Motley Fool

3 Monster Stocks in the Making ↗

November 23, 2024

Via The Motley Fool

Deciphering Disruption: Inside Cathie Wood's Latest Plays

November 16, 2024

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

Via MarketBeat

Topics Artificial Intelligence ETFs

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More ↗

November 16, 2024

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.